HCC molecular-subtype assignment and cohort-specific outcome comparisons
Integrated-omics analysis defines subtypes of hepatocellular carcinoma based on circadian rhythm
Year: 2025 · Journal: Journal of Integrative Medicine · Publication type: Article
Author evidence page · Formal publication DOI · BibTeX · RIS · CSL JSON
Which HCC subtypes were associated with clinical outcomes?
TCGA-LIHC analysis identified CS-H, CS-L and CS-M, with poorer outcomes associated with CS-H. TCGA-LIHC n: 369; Subtypes: CS-H; CS-L; CS-M. Association does not establish that circadian disruption causes liver cancer or constitute a validated clinical decision rule.
- KF3 — Author-deposited full text: Results 3.3-3.4; Fig. 4
Were external classification and survival analyses performed in identical cohorts?
External subtype and survival analyses used overlapping but different cohort sets. Fig. 5A datasets: ICGC_LIRI; GSE14520; GSE54236; GSE104580; Fig. 5B datasets: ICGC_LIRI; GSE14520; GSE54236; GSE27150. Do not claim that all five cohorts validated survival, or add the two four-cohort analyses as eight independent cohorts.
- KF4 — Author-deposited full text: Results 3.5; Fig. 5 legend
Do the immune analyses demonstrate immunotherapy benefit?
Subtypes differed in proliferation/metabolic programs and inferred immune characteristics. Analyses: Expression enrichment; CIBERSORT; IPS. IPS and immune deconvolution are not an observed immunotherapy-response trial.
- KF5 — Author-deposited full text: Results 3.6-3.7; Fig. 6
Reviewed study profile
- profile type
- multicohort_omics
- study design
- Public single-cell and bulk transcriptomic integration with retrospective subtype evaluation
- evidence type
- Human molecular association and cross-dataset classification analysis
- population
- HCC expression cohorts, with separate circadian reference experiments
- primary endpoint
- HCCcrds-associated molecular subtype structure
- secondary endpoint
- Retrospective outcome associations and computational biological annotations
- data modalities
- single-cell RNA sequencing
- bulk transcriptomics
- co-expression analysis
- LRA clustering/NTP
- immune deconvolution
- external validation
- true
- scale metrics
- label
- TCGA-LIHC
- value
- 369 samples in the reported analysis
- label
- GSE149614 analyzed cells
- value
- 11,383 cells
- label
- External datasets
- value
- 5 datasets with different analytical roles
- counting note
- Cell counts, candidate genes, HCC cohort samples and separate circadian reference experiments are different units. No complete unique-participant total is inferred. The five external datasets have different analytical uses: the four Fig. 5A and four Fig. 5B sets overlap but are not identical and must not be added as eight independent cohorts. External validation means retrospective cross-dataset expression/classification evaluation, not prospective clinical utility or direct physiological rhythm measurement in HCC patients.
Complete reviewed evidence scope
- supports
- Single-cell modules supplied the HCCcrds gene set.
- The score was evaluated in separate clock, feeding and sleep-reference data.
- TCGA-LIHC analysis identified CS-H, CS-L and CS-M, with poorer outcomes associated with CS-H.
- External subtype and survival analyses used overlapping but different cohort sets.
- Subtypes differed in proliferation/metabolic programs and inferred immune characteristics.
- NNMT and MARCKSL1 were among subtype-associated candidate genes.
- does not establish
- Prospective diagnostic or prognostic clinical utility.
- Direct individual measurement of physiological circadian phase or amplitude.
- Circadian disruption as a demonstrated cause of cancer.
- Clinical benefit from score-guided treatment.
- IPS as measured response in patients receiving immunotherapy.
- Therapeutic validation of the candidate genes.
- Completed page-by-page equivalence checking between the author-deposited text and final typeset version.
- Unprovided AUCs, hazard ratios, participant totals or additional omics modalities.
Complete reviewed limitations
- Cell counts, candidate genes, HCC cohort samples and separate circadian reference experiments are different units. No complete unique-participant total is inferred. The five external datasets have different analytical uses: the four Fig. 5A and four Fig. 5B sets overlap but are not identical and must not be added as eight independent cohorts. External validation means retrospective cross-dataset expression/classification evaluation, not prospective clinical utility or direct physiological rhythm measurement in HCC patients.
- Cells and candidate genes are not patient counts or demonstrated causal regulators.
- Reference-experiment evaluation does not mean HCC patients underwent longitudinal physiological circadian measurements.
- Association does not establish that circadian disruption causes liver cancer or constitute a validated clinical decision rule.
- Do not claim that all five cohorts validated survival, or add the two four-cohort analyses as eight independent cohorts.
- IPS and immune deconvolution are not an observed immunotherapy-response trial.
- This evidence synthesis does not claim independent causal intervention or therapeutic validation of these genes.
- Prospective diagnostic or prognostic clinical utility.
- Direct individual measurement of physiological circadian phase or amplitude.
- Circadian disruption as a demonstrated cause of cancer.
- Clinical benefit from score-guided treatment.
- IPS as measured response in patients receiving immunotherapy.
- Therapeutic validation of the candidate genes.
- Completed page-by-page equivalence checking between the author-deposited text and final typeset version.
- Unprovided AUCs, hazard ratios, participant totals or additional omics modalities.
- Bibliographic identity was checked against the final PubMed/publisher record. Detailed evidence locators refer to the author-deposited full text; final typeset figure-level equivalence was not independently re-established.